D.J.J. Hermans, C.G. Bauland, J. Zweegers, I.M. van Beynum and C.J.M. van der Vleuten Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions British Journal of Dermatology 168
What’s already known about this topic?
After the discovery of its efficacy in infantile haemangioma (IH) in 2008, propranolol is becoming the first-choice treatment for these benign tumours with (impending) complications.
Only small series with limited follow-up have been published to date.
What does this study add?
This study provides prospectively collected data on indications and safety in a large patient group with IH in a single centre.
‘Real clinical practice’ data are given to guide future use of propranolol in IH. Based on its apparent safety, prescription of propranolol may go beyond strictly medical indications.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf